Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

By G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperierre and 2 more. Journal of Clinical Oncology, 2006

698 citations recorded by the source corpus.

Subfields: Genetics, Neurology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/aee9e14a8be458e63e22b465826122e7be766dd3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Guido Reifenberger
2. Michael Weller
3. R. Jenkins

Citations in the corpus

• Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009, background): “Allelic losses on chromosome arms 1p and 19q are associated with a favorable prognosis in patients with oligodendroglial and oligoastrocytic anaplastic gliomas treated with radiotherapy or radiotherapy plus chemotherapy.(6-9) MGMT promoter hypermethylation is associated with prolonged progression-fr”
• Long-term survival with glioblastoma multiforme. (2007, background): “In contrast to anaplastic oligodendrogliomas and oligoastrocytomas (Cairncross et al., 2006; van den Bent et al., 2006), the prognostic significance of 1p/19q deletion in glioblastomas is not clear yet (Ino et al., 2000; Schmidt et al., 2002; Brat et al., 2004; Houillier et al., 2006).”
• A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. (2006, background): “Similar trends were observed for the association of OS after RT and PCV with fusion status and for the associations of OS and PFS after RT and PCV with combined 1p and 19q deletion (Table 3; data not shown), but the Ps were not significant.”
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. (2013, methodology): “Protocol Compliance PCV was administered per protocol or acceptably in 95% of patients; the percentage receiving four, three, two, one, and no cycles was 54%, 22%, 9%, 12%, and 2%, respectively.(19) PCV was stopped for progression or death in 17%, toxicity in 20%, and other reasons in 15%.”